Policy and Advocacy Update: December 2022
There were many substantial legislative moments for psychedelics in 2022. States and municipalities across the country continue to seriously consider making changes to their laws governing psychedelic …
Uncategorized
Jury Finds in Favor of Plaintiffs in Trial on Harm Reduction and Medical Responsibility
On November 30, 2022, the jury in CARLA GATLIN, et al. vs DO LAB INC, et al. found in favor of the plaintiffs on the issues of medical responsibility and damages related to the death of a 20-year old woman …
A Psychedelic Caucus is Coming to Congress
November 17, 2022 MAPS celebrates the formation of the Congressional Psychedelics Advancing Clinical Treatments (PACT) Caucus, announced today. Led by Representatives Lou Correa (D-CA) and Jack Bergman …
Protected: Second MAPS-Sponsored Phase 3 Trial of MDMA-Assisted Therapy for PTSD Completed
There is no excerpt because this is a protected post.
Psilocybin Facilitator Training Programs in Oregon: An Inside Look at Oregon’s Burgeoning Psychedelic Marketplace
Conflict of Interest Disclosure: Jon Dennis is the executive director and a co-owner of the Vital Oregon facilitator training program, and this article is about Oregon facilitator training programs. …
MDMA Therapy Training Program Update: September 2022
In August, the training team hosted the first MAPS PBC Trainers Retreat. The 4-day retreat was delivered in collaboration with Reconsider. The gathering brought together more than 25 MAPS PBC trainers …
Disclosure: IUSA5: A Randomized, Delayed Treatment Control Phase 2 Study of the Safety and Effectiveness of Manualized MDMA-Assisted Therapy for the Treatment of Social Anxiety Disorder
Social Anxiety MDMA-Assisted Therapy Investigation (SAMATI) Jason Luoma, Ph.D., of Portland Psychotherapy, is the sponsor and Principal Investigator for SAMATI, an exploratory study to investigate the …
Phase 2 Study of Cannabis for Veterans with PTSD (MJP2) Regulatory Correspondences with FDA
Study MJP2 protocol was initially submitted on March 9, 2021. The study was put on hold by FDA on May 10, 2021 with additional comments for the hold provided on June 3, 2021. MAPS provided FDA with a response …
Christie’s Announces Cartography of the Mind: A Curated NFT Sale to Benefit MAPS
Christie’s is pleased to present Cartography of the Mind, a Curated NFT Sale to benefit the Multidisciplinary Association for Psychedelic Studies (MAPS) in collaboration with Ryan Zurrer, founder of …
Participant Experiences & “Cover Story”
We encourage you to read and follow maps.org/safety for detailed information regardingMAPS Code of Ethics for Psychedelic Psychotherapyand our practices to create a culture of safety in psychedelic therapy. …
atai Impact Donates to MAPS to Support Pioneering Work in Psychedelic Medicine
FOR IMMEDIATE RELEASE Leading non-profit and commercial organizations in psychedelic science united in visions to heal mental health conditions Donation is from atai Impact, the philanthropic arm of mental …
MAPS PBC Adopts Charter for Independent Ethics Review Board
FOR IMMEDIATE RELEASE Independent members will inform continual iteration and improvement of ethical governance of MDMA-assisted therapy research and therapist training program Independent Ethical Review …